Immunotech Laboratories ITV-1 Manufacturing Announcement

MONROVIA, Calif., May 30, 2013 (GLOBE NEWSWIRE) -- Immunotech Laboratories, Inc. (Pink Sheets:IMMB) today announced the company has reached advanced negotiations for the production of Immunotech's ITV-1 Medicine with a reputed Contract manufacturing facility, for use in the Bulgarian Clinical Studies. All costs related to the production of the ITV-1 for this production will be facilitated by Immunotech's sister company in Bulgaria. (Immunotech BG).

Immunotech President & Founder, Harry Zhabilov today announced this is an advancement for Immunotech's Aids-HIV treatment in the steps towards application for FDA approval of the Treatment for use in the USA.

Previously the company announced for the Bulgarian Clinical Trials: "We have negotiated with two of the biggest hospitals in Bulgaria (thus, European Union) to carry our clinical trials of IPF-ITV-1 and ITV-2 as follows: At the Infectious Disease Hospital, Sofia we will carry out clinical trials of ITV-1 with 50 patients infected with HIV-AIDS in combination with one protease inhibitor. At the Military Hospital, Sofia, with Hospital Director Prof. General Stoyan Tonev we will carry out clinical trials of ITV-2 with 50 patients ill with chronic hepatitis in its most advanced stage. The clinical trials will be conducted parallel with protease inhibitor".

About Immunotech Laboratories

Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases such as HIV and Aids.

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

CONTACT: Company Contact: Public Relations: The Nabors Group: 713-875-9200 E-mail:

Source:Immunotech Laboratories